# A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

> **NCT05040568** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Colon Cancer
- Resected Stage

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Expanded CB-NK cells
- **DRUG:** Fludarabine phosphate
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05040568
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-28
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040568, "A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05040568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*